C.H. Yi and D.K. Sogah contributed equally to this paper.

Abbreviations used in this paper: Chn, Charlatan; DIAP1, *Drosophila* inhibitor of apoptosis 1; dox, doxorubicin; dsRNA, double-stranded RNA; NRSF, neuron-restrictive silencer factor; REST, RE1-silencing transcription factor.

Introduction
============

Apoptosis is an evolutionally conserved cell death pathway that regulates development and tissue homeostasis. Caspases, a family of cysteine proteases, play a critical role in mediating the execution of apoptosis. Although CED-3 is the sole caspase required for programmed cell death in *Caenorhabditis elegans*, multiple caspases mediate apoptotic cell death in flies and mammals. In these systems, the activation of upstream initiator caspases in response to proapoptotic signals leads to activation of the downstream executioner caspases. Although the core apoptotic pathway has been studied extensively, many aspects of the signaling networks that control the cellular decision to undergo apoptosis remain unknown. Complex biological processes have been dissected successfully using genome-wide RNAi screens in *Drosophila melanogaster* cells. In this study, we describe the isolation of 10 genes, including the apical caspase Dronc, that are required for full caspase activation in response to DNA damage. Surprisingly, we discovered that Charlatan (Chn), a regulator of neuronal cell differentiation ([@bib21]), and ARD1, an *N*-acetyltransferase involved in cell fate specification ([@bib26]), regulate caspase activation. Importantly, we show that certain fly genes are functionally conserved as modifiers of caspase activation in the mammalian system. Our screen implicates Chn and ARD1 as a molecular link between cellular differentiation and apoptosis.

Results and discussion
======================

To determine the feasibility of an RNAi approach in identifying apoptotic regulators, we tested whether the knockdown of Dcp-1, a downstream effector caspase functionally similar to mammalian caspase-3, protects against DNA damage--induced apoptosis in *Drosophila* embryonic hemocyte Kc cells ([@bib20]). We used a topoisomerase II inhibitor, doxorubicin (dox), to induce dose-dependent cell death (Fig. S1 A, available at <http://www.jcb.org/cgi/content/full/jcb.200708090/DC1>) that can be suppressed by z-VAD.fmk treatment (Fig. S1 B). As expected, *dcp-1* RNAi partially protected cells from apoptosis induced by dox (Fig. S1 C), which is consistent with previous observations ([@bib30]). We conclude that dox induces caspase-dependent cell death in Kc cells that can be suppressed by a specific double-stranded RNA (dsRNA) and, therefore, represents a suitable system for identifying modulators of apoptosis.

A diverse set of dsRNAs protects fly cells from dox-induced apoptosis
---------------------------------------------------------------------

To identify dsRNAs that inhibit DNA damage--induced apoptosis in Kc cells, we performed a high-throughput screen using an established genome-wide *Drosophila* RNAi library that targets 19,470 genes ([@bib5]). 81 dsRNAs resulted in a z score \>2, which was the threshold for defining a hit in our primary screen ([Fig. 1 A](#fig1){ref-type="fig"}). To eliminate dsRNAs that directly enhanced cellular ATP levels, the effect of dsRNAs on ATP levels was measured in the rescreen. We verified that 62 dsRNAs specifically protected cells against dox-induced apoptosis ([Fig. 1 B](#fig1){ref-type="fig"}). To minimize off-target effects, we further examined any dsRNA with at least 19-nucleotide sequence identity with an off-target gene ([@bib10]; [@bib13]) by testing alternative dsRNAs distinct from the original targeting sequence for protection against cell death induced by dox treatment (Fig. S2 A, available at <http://www.jcb.org/cgi/content/full/jcb.200708090/DC1>) and for caspase suppression induced by *Drosophila* inhibitor of apoptosis 1 (*diap1*) RNAi treatment as described in [Fig. 3](#fig3){ref-type="fig"} (Fig. S2 B). Any dsRNA for a given gene failing to provide significant protection (P \< 0.05) in either of these assays was eliminated, resulting in a final set of 47 genes ([Fig. 1 B](#fig1){ref-type="fig"} and Table S1).

![**Identification and confirmation of dsRNAs that provide protection against DNA damage--induced apoptosis.** (A) dsRNAs were screened in duplicate plates for protection against dox treatment. The threshold for a hit was set at a z score of at least 2 for both plates (above blue dashed line). The plot represents the z score analysis of several plates that were enriched for the genes shown in [Table I](#tbl1){ref-type="table"} (red diamonds). (B) dsRNAs identified in the primary screen were individually tested, and those that provided statistically significant protection against dox in at least two independent experiments are shown (P \< 0.05; *t* test). The graph represents a pool of 10 sample plates, and the error bars represent the SD of dsRNAs tested in triplicate. (C) This graph depicts the functional distribution of genes shown in B according to information provided by FlyBase (version FB2006_01).](jcb1790619f01){#fig1}

The identification of three known regulators of cell death validates the ability of our screen to uncover genes required for promoting apoptosis. Silencing of Dronc provided maximal protection against dox treatment ([Fig. 1 B](#fig1){ref-type="fig"}), which is consistent with its role as the main checkpoint for apoptosis in the fly ([@bib7]; [@bib9]). In addition, knockdown of the ecdysone-induced protein Eip63F-1 provided the fourth strongest protection against DNA damage. The increased expression of Eip63F is detected in the premetamorphic salivary gland of *Drosophila* larvae, immediately before the ecdysone-mediated induction of massive autophagic cell death ([@bib11]; [@bib18]). Lastly, our screen isolated Jra, the *Drosophila* orthologue of a known proapoptotic mammalian transcriptional factor, c-Jun, as a mediator of DNA damage--induced apoptosis ([@bib22]).

Approximately 85% of the genes identified in the RNAi screen are characterized genes of known function or contain well-conserved functional domains, which regulate a wide range of cellular processes, including signaling, metabolism, and transcription, whereas the remaining 15% of the genes have no known functional domains ([Fig. 1 C](#fig1){ref-type="fig"}). Altogether, our RNAi screen implicates cell death genes (three), signaling molecules (13), metabolic regulators (10), metabolite transport factors (four), genes involved in ER/Golgi trafficking (four), chromatin/transcription regulators (two), RNA-processing factors (two), structural and cytoskeletal proteins (two), and genes of unknown function (seven) in mediating DNA damage--induced apoptosis (Table S1). Strikingly, 20% of the genes are directly involved in cellular metabolic processes ([Fig. 1 C](#fig1){ref-type="fig"}), supporting an earlier proposal that the cellular metabolic state critically influences the threshold for induction of apoptosis ([@bib12]). To investigate where these genes operate in the apoptotic pathway, we conducted specific enzymatic and epistatic assays in fly and mammalian cells.

Identification of genes involved in caspase-dependent cell death
----------------------------------------------------------------

Next, we classified the genes that are specifically involved in caspase-dependent cell death. We observed the substantial induction of caspase activity 8 h after dox treatment, preceding detectable cell death (Fig. S1, A and D). Any RNAi suppressing this activity implicates the target gene in early regulation of caspase activation. In addition to *dcp-1* RNAi, knockdown of *dronc* and *jra* significantly (P \< 0.05) suppressed caspase-3/7--like activity in the presence of dox, whereas the negative control, RNAi against calpain A, a calcium-dependent cysteine protease, did not affect this pathway ([Fig. 2 A](#fig2){ref-type="fig"}). We expanded this analysis to all of the genes identified in the initial RNAi screen and discovered 20 dsRNAs that suppressed caspase activation induced by DNA damage (Table S1). Interestingly, as shown in [Fig. 2 B](#fig2){ref-type="fig"}, 12 of these genes were found to be epistatic to *diap1*, as discussed in the next section.

![**Classification of genes that function upstream of the executioner caspases.** (A) Kc cells were transfected with dsRNAs as indicated and treated with dox to induce caspase activation. This graph is representative of three independent experiments. RLU, relative light unit. (B) dsRNAs were tested for the suppression of caspase activity induced by dox treatment. Selected dsRNAs that provided statistically significant inhibition of caspase activity in at least two independent experiments are shown (\*, P \< 0.05; *t* test). This graph shows a pool of six sample plates. The error bars represent the SD of dsRNAs tested in triplicate.](jcb1790619f02){#fig2}

Identification of genes epistatic to DIAP1
------------------------------------------

Next, we performed *diap1* epistatic analysis to further categorize the genes. DIAP1, the fly orthologue of the mammalian inhibitors of apoptosis proteins, is a direct inhibitor of caspases, and deficiency in DIAP1 leads to rapid caspase activation and apoptosis in vivo ([@bib23]). Thus, apoptosis induced by the loss of DIAP1 presents an alternative apoptotic assay independent of DNA damage. Silencing of genes that regulate activation of the core apoptotic machinery may provide protection against apoptosis induced by both DNA damage and the loss of DIAP1. RNAi against *dcp-1* partially suppressed cell death induced by the depletion of DIAP1 in Kc cells ([Fig. 3 A](#fig3){ref-type="fig"}). Also, *dronc* RNAi potently protected cells against apoptosis induced by deficiency in DIAP1 as reported previously ([@bib14]; [@bib6]). Altogether, 32 of the genes confirmed from our primary screen provided significant (P \< 0.05) protection against cell death induced by the silencing of DIAP1 (Table S1 and [Fig. 3 B](#fig3){ref-type="fig"}).

![**A set of genes epistatic to Diap1 and critical for caspase activation.** (A) Kc cells were transfected with dsRNAs as indicated followed by transfection with RNAi against *diap1*. This graph is representative of three independent experiments. (B) dsRNAs were tested for protection against cell death induced by the loss of Diap1. Selected dsRNAs that provided statistically significant protection against *diap1* RNAi in at least two independent experiments are shown. This graph represents a pool of three sample plates. (C) dsRNAs were tested for suppression of caspase activation induced by the loss of Diap1. Note that 10/12 dsRNAs showed statistically significant suppression of caspase activation compared with RNAi against *diap1* only. This graph is representative of three independent experiments. The error bars represent the SD of dsRNAs tested in triplicate. \*, P \< 0.05; *t* test.](jcb1790619f03){#fig3}

Interestingly, 12 dsRNAs suppressed caspase-3/7--like activity after dox treatment and protected against cell death induced by *diap1* RNAi, suggesting that these genes are required for apoptosis induced by multiple stimuli ([Table I](#tbl1){ref-type="table"}). To confirm that these genes are necessary for the full activation of caspases, we determined whether these dsRNAs could suppress spontaneous caspase activity induced by *diap1* RNAi. We observed maximal induction of caspase activity by *diap1* RNAi after 24 h, and this effect was completely suppressed by dsRNA against *dcp-1* (Fig. S1 E). Importantly, ablating 10/12 dsRNAs resulted in the significant (P \< 0.05) suppression of caspase activity compared with *diap1* RNAi only ([Fig. 3 C](#fig3){ref-type="fig"}).

###### A summary of the genes identified in the RNAi screen that modulate caspase activation

  -----------------------------------------------------------------------------------------------
  Gene ID   Gene name         Known mammalian\   Gene ontology                 Functional class
                              orthologue                                       
  --------- ----------------- ------------------ ----------------------------- ------------------
  CG8090    Dronc (Nc)        Caspase            Apical caspase                Cell death

  CG5410    dMiro             Miro               Mitochondrial GTPase          Signaling

  CG11989   dARD1             hARD1              Protein acetyltransferase     Signaling

  CG14740   NA                Cs                 Citrate synthase              Metabolism

  CG31674   NA                GRHPR              Glyoxylate reductase          Metabolism

  CG12170   NA                OXSM               Fatty acid biosynthesis       Metabolism

  CG10725   NA                NA                 Polysaccharide metabolism     Metabolism

  CG9258    nrv1              Atp1b1             Na^+^/K^+^ATPase              Transporters

  CG8029    NA                NA                 Proton-coupled ATP synthase   Transporters

  CG7438    myo31DF           Myo1D              Type 1 myosin                 Transporters

  CG11798   Charlatan (chn)   NRSF/REST          Transcriptional repressor     Transcription

  CG6712    NA                RPF1               Ribosomal RNA processing      RNA processing
  -----------------------------------------------------------------------------------------------

NA, not applicable.

In addition to *dronc* RNAi, dsRNAs targeting *chn* and *dARD1* provided the strongest suppression of spontaneous caspase activity. Consistent with our observation that RNAi against *chn* protects against DNA damage--induced cell death, the mammalian orthologue neuron-restrictive silencer factor (NRSF)/RE1-silencing transcription factor (REST) was recently identified as a candidate tumor suppressor in epithelial cells ([@bib25]). Previous work indicates that Chn and NRSF/REST function as a transcriptional repressor of neuronal-specific genes ([@bib8]; [@bib19]; [@bib21]), suggesting that cellular differentiation may render cells refractory to caspase activation and apoptosis. Also, we identified several metabolic genes, CG31674, CG14740, and CG12170, that may be involved in the general regulation of caspase activation. Recently, [@bib16] demonstrated that NADPH produced by the pentose phosphate pathway regulates the activation of caspase-2 in nutrient-deprived *Xenopus laevis* oocytes. Together with our results, these observations provide further evidence for an intimate link between the regulation of metabolism and induction of apoptosis.

Evolutionary conservation of the novel regulators of apoptosis
--------------------------------------------------------------

To further explore the significance of our findings, we examined whether silencing the mammalian orthologues of the fly genes identified from the RNAi screen confers protection against dox-induced cell death in mammalian cells. We selected a set of mammalian orthologues that are believed to be nonredundant. The list includes the orthologues of dMiro, which functions as a Rho-like GTPase; dARD1, which functions as an *N*-acetyltransferase; CG12170, which functions as a fatty acid synthase; and Chn, which functions as a transcriptional repressor (RHOT1, hARD1, OXSM, and REST, respectively; FlyBase). In addition, we tested Plk3, a mammalian orthologue of Polo, as dsRNA targeting *polo* potently protected against dox treatment ([Fig. 1](#fig1){ref-type="fig"}).

We assessed the ability of siRNAs targeting a gene of interest to protect against DNA damage in HeLa cells. As a positive control, cells were transfected with siRNAs targeting Bax or Bak, two central regulators of mammalian cell death ([@bib24]; [@bib31]). Indeed, silencing of Bax or Bak resulted in significant protection (P \< 0.05) against dox- induced cell death ([Fig. 4 A](#fig4){ref-type="fig"}). We observed that plk3 RNAi provided partial protection against dox treatment, which is consistent with previous studies implicating Plk3 in stress-induced apoptosis ([@bib28],[@bib29]; [@bib3]). Interestingly, the knockdown of hARD1 dramatically enhanced cell survival in the presence of dox to levels similar to that of Bak. This protective effect was also evident at the morphological level. In cells transfected with a nontargeting control siRNA, dox treatment resulted in typical apoptotic morphology, including cell rounding and membrane blebbing ([Fig. 4 B](#fig4){ref-type="fig"}). In direct contrast, cells transfected with siRNAs against hARD1 maintained a normal and healthy morphology and continued to proliferate in the presence of dox.

![**hARD1 is required for caspase activation in response to DNA damage in mammalian cells.** (A) HeLa cells were transfected with a pool of four siRNAs as indicated followed by treatment with 1.25 μg/ml dox for 20 h. This graph is representative of three independent experiments. (B) HeLa cells were transfected with siRNAs as indicated and treated with 1.25 μg/ml dox followed by a 12-h incubation. Cells were visualized by bright-field microscopy, and representative images of samples tested in triplicate are shown. (C) HeLa cells were transfected with siRNAs as indicated and were treated with 5 μg/ml dox for 8 h. This graph is representative of three independent experiments. (D) HeLa cells were transfected with a pool of siRNAs or individual siRNAs targeting hARD1 as indicated and were treated with 1.25 μg/ml dox for 20 h. This graph is representative of three independent experiments. (E) HeLa cells were transfected with siRNAs as indicated and treated with 5 μg/ml dox for 8 h. Note that RNAi against hARD1 completely inhibited the cleavage of caspase-2, caspase-9, and caspase-3 compared with nontargeting siRNA (arrows). This experiment is representative of two independent experiments. (F) HeLa cells were transfected with siRNAs as indicated and treated with 5 μg/ml dox for 8 h. Asterisks represent nonspecific bands recognized by the indicated antibody. This experiment is representative of two independent experiments. (A, C, and D) \*, P \< 0.05; *t* test. Error bars represent SD.](jcb1790619f04){#fig4}

To examine whether the protection provided by siRNAs targeting hARD1 and plk3 is associated with the suppression of caspase activation, we measured caspase activity in these cells treated with dox. RNAi against plk3 provided partial suppression of caspase activity, again supporting the protection phenotype observed in [Fig. 4 A](#fig4){ref-type="fig"}. Interestingly, the depletion of REST resulted in some suppression of caspase activity in the presence of dox even though the protection against cell death was not statistically significant ([Fig. 4 C](#fig4){ref-type="fig"}). Consistent with our viability assay, complete suppression of caspase-3/7 activity was observed in cells transfected with hARD1 siRNA ([Fig. 4 C](#fig4){ref-type="fig"}). These results indicate that hARD1 is required for caspase-dependent cell death induced by DNA damage. Furthermore, we observed that all four siRNAs targeting hARD1 were individually capable of providing robust protection against cell death, strongly suggesting that these siRNAs target hARD1 specifically ([Fig. 4 D](#fig4){ref-type="fig"}).

Because the silencing of hARD1 dramatically suppressed activation of the downstream caspases, we examined whether activation of the upstream caspases in response to dox treatment is also perturbed. Remarkably, hARD1 RNAi inhibited the cleavage of caspase-2 and -9 in cells treated with dox, whereas caspase cleavage was readily detected in control cells ([Fig. 4 E](#fig4){ref-type="fig"}). Thus, we propose that hARD1 regulates the signal transduction pathway apical to the apoptotic machinery in the DNA damage response itself or the activation of upstream caspases.

Consistent with the results of the caspase-3/7 assay ([Fig. 4 C](#fig4){ref-type="fig"}), silencing of hARD1 completely inhibited the appearance of activated caspase-3 induced by dox ([Fig. 4 E](#fig4){ref-type="fig"}). We used this assay for a hARD1 complementation experiment to demonstrate the proapoptotic role of hARD1 in response to DNA damage. We used a new siRNA pool targeting the 5′ untranslated region of hARD1 (5′si), which inhibited caspase-3 cleavage induced by dox treatment ([Fig. 4 F](#fig4){ref-type="fig"}). Furthermore, we observed caspase-3 cleavage in reconstituted hARD1 knockdown cells. Because six out of six siRNAs against hARD1 provided strong protection against DNA damage--induced apoptosis and complementation of hARD1-sensitized cells to caspase activation, we conclude that the functional role of ARD1 for dox-induced apoptosis is evolutionally conserved from *Drosophila* to mammals.

In contrast to our results, [@bib2] reported that hARD1 is necessary to maintain cell survival. One possible explanation for this discrepancy can be attributed to the inherent differences between the siRNAs used in this study and that used by Arnesen et al. We observed that two out of two siRNAs used in the [@bib2] study resulted in a decrease in cell survival in the absence of stress signal, whereas none of the siRNAs tested as such had a negative effect on cell survival (Fig. S2 D).

In summary, we used an unbiased RNAi screening platform in *Drosophila* cells to identify genes involved in promoting DNA damage--induced apoptosis. We isolated 47 dsRNAs that suppress cell death induced by dox. These genes encode for known apoptotic regulators such as Dronc, the *Drosophila* orthologue of the known proapoptotic transcriptional factor c-Jun, and an ecdysone-regulated protein, Eip63F-1, thereby validating our primary screen. Furthermore, our study implicates a large class of metabolic genes that were previously not suspected to have a role in modulating caspase activation and apoptosis, such as genes involved in fatty acid biosynthesis (CG11798), amino acid/carbohydrate metabolism (CG31674), citrate metabolism (CG14740), complex carbohydrate metabolism (CG10725), and ribosome biosynthesis (CG6712). These results support an earlier proposal ([@bib12]; [@bib16]) that the cellular metabolic status regulates the threshold for activation of apoptosis and thus plays a critical role in the decision of a cell to live or die.

Of particular interest is the identification of ARD1. We present evidence that RNAi against ARD1 provides protection against cell death and leads to the suppression of caspase activation induced by DNA damage in fly cells and HeLa cells. Furthermore, deficiency in dARD1 renders fly cells resistant to the spontaneous caspase activity and cell death associated with loss of Diap1. Importantly, we provide substantial evidence that hARD1 is required for caspase activation in the presence of DNA damage in mammalian cells. Cleavage of initiator and executioner caspases are suppressed in hARD1 RNAi cells treated with dox, suggesting that hARD1 functions further upstream of caspase activation, and the complementation of hARD1 knockdown cells restores caspase-3 cleavage. These data indicate that ARD1 is necessary for DNA damage--induced apoptosis in flies and mammals.

ARD1 functions in a complex with *N*-acetyltransferase to catalyze the acetylation of the N^α^-terminal residue of newly synthesized polypeptides and has been implicated in the regulation of heterochromatin, DNA repair, and the maintenance of genomic stability in yeast ([@bib15]; [@bib1]; [@bib17]; [@bib27]; [@bib4]). These studies suggest that ARD1 may be involved in regulating an early step in response to DNA damage. We anticipate that future studies will focus on determining whether ARD1 functions in similar processes in mammals. The diversity of genes identified in our screen illustrates the complex cellular integration of survival and death signals through multiple pathways.

Materials and methods
=====================

Tissue culture
--------------

*Drosophila* Kc~167~ cells were maintained in Schneider\'s *Drosophila* medium with 10% FBS in the presence of penicillin and streptomycin (Invitrogen). HeLa cells were maintained in DME with 10% newborn calf serum in the presence of penicillin and streptomycin (Invitrogen) and were passaged for no more than 6 wk.

RNAi screening
--------------

*Drosophila* Kc cells (10^5^/well in 384-well plates) were transfected with prealiquoted dsRNAs (0.5 μg/well) followed by a 48-h incubation to allow for protein turnover. Subsequently, cells were treated with 5 μg/ml dox (Sigma-Aldrich) for an additional 48-h incubation. Cell viability was determined by measuring cellular ATP levels (CellTiter-Glo luminescent cell viability assay; Promega). Positive hits for this screen were defined as dsRNAs that increased cellular ATP levels by at least two units of SD above the mean level of the plate, a z score of two, in duplicate.

Rescreen
--------

Confirmation of these hits was performed using newly synthesized dsRNAs. cDNA was amplified from fly genomic DNA using primers optimally designed for RNAi (sequences provided by N. Ramadan, *Drosophila* RNAi Screening Center, Harvard Medical School, Boston, MA). dsRNA synthesis was conducted according to the manufacturer\'s recommended protocol (MEGAscript; Ambion). Kc cells (2 × 10^5^/well in 96-well plates) were transfected with dsRNAs (1 μg/well) followed by treatment with dox. Each dsRNA was tested in triplicate and in at least two independent experiments. Cell viability was determined as a ratio between ATP levels of cells treated with a given dsRNA in the presence of dox and control cells treated with the dsRNA only. Statistically significant protection (P \< 0.05) against dox-induced cell death was determined by comparing the cell viability of cells treated with RNAi in the presence of dox with the cell viability of cells treated with dox alone. Fold protection against dox was determined as the ratio between the mean cell viability of cells transfected with dsRNA in the presence of dox and cells treated with only dox.

Caspase activation assay
------------------------

Kc cells were transfected in 96-well plates with the 62 dsRNAs that were confirmed in the primary screen followed by treatment with dox for 8 h to induce caspase activation. Each dsRNA was tested in triplicate and in at least two independent experiments. Caspase-3/7--like activity was quantified using a luciferin-labeled DEVD peptide substrate (Caspase-Glo 3/7 assay; Promega). Fold caspase-3/7--like activity was determined as the ratio between the mean caspase-3/7--like activity of cells transfected with dsRNA in the presence of dox and cells treated with dox only.

DIAP1 epistasis studies
-----------------------

Kc cells were transfected in 96-well plates with individual dsRNAs targeting the 62 genes confirmed in the initial screen. After a 24-h incubation, these cells were transfected with 1 μg *diap1* dsRNA for an additional 48-h incubation when cell viability was quantified (as described in the Rescreen section). Fold protection against *diap1* RNAi was determined as the ratio between the mean cell viability of cells transfected with the indicated dsRNA and *diap1* RNAi and the mean cell viability of cells transfected with *diap1* RNAi only. For the caspase activation assay, Kc cells were transfected with dsRNA as indicated followed by transfection with dsRNA against *diap1* and an additional 24-h incubation.

Mammalian RNAi studies
----------------------

Low-passage HeLa cells were transiently transfected (5 × 10^5^/well in 96-well plates) with a pool of four siRNAs unless otherwise indicated (50 nM; predesigned ON-TARGETplus siRNAs; Dharmacon) using HiPerFect transfection reagent (QIAGEN). After a 48-h incubation, cells were treated with dox (concentrations and incubation times are noted in figures). siRNAs were tested in triplicate for each independent experiment. Cell viability and caspase-3/7 activity was quantified as described for KC cells. Images were obtained using bright-field microscopy.

For detection of caspase cleavage, HeLa cells were transfected with siRNAs (1.5 × 10^5^/well in six-well plates) followed by treatment with dox. Cells were lysed directly in SDS sample buffer and subjected to SDS-PAGE analysis. Caspases were detected by immunoblotting using the following antibodies: caspase-9 (R&D Systems), caspase-2 (Alexis), caspase-3 (Cell Signaling Technology), and cleaved caspase-3 (Cell Signaling Technology). hARD1 was detected using a rabbit polyclonal antibody (provided by M.C. Brahimi-Horn, University of Nice, Centre National de la Recherche Scientifique, Nice, France).

For hARD1 reconstitution experiments, HeLa cells were transfected with a pool of two siRNAs targeting the 5′ untranslated region of hARD1 (sequences CUGACUGCGCCUUCACGAUUU and GCUGACUGCGCCUUCACGAUU; Dharmacon) in six-well plates followed by a 24-h incubation. This was followed by transient transfection of C-terminal--tagged hARD1-*myc*/his using TransIT-LT1 transfection reagent (Mirus) and an additional 24-h incubation. After dox treatment, cells were lysed and analyzed by Western blotting.

Microscopy
----------

Images of HeLa cells were obtained using a microscope (Eclipse TE300; Nikon) with a 10× Ph L objective lens and a camera (ORCA-ER; Hamamatsu) at room temperature. Openlab 3.1.7 acquisition software (Improvision) was used to analyze the images.

Online supplemental material
----------------------------

Fig. S1 shows a characterization of dox-induced cell death and controls for RNAi screen. Fig. S2 presents semiquantitative analysis of dsRNAs to validate the RNAi library. Table S1 provides a comprehensive list of genes identified in the primary screen. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200708090/DC1>.
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